Rein Therapeutics doses first patient in Phase 2 trial of LTI-03

Rein Therapeutics (RNTX) dosed the first patient in its Phase 2 clinical trial evaluating LTI-03 for idiopathic pulmonary fibrosis, a progressive and fatal lung disease with limited treatment options. The Phase 2 study is a randomized, double-blind, placebo-controlled trial designed to evaluate the safety, tolerability, and impact to lung function and structure of LTI-03, an inhaled therapy intended to regulate multiple fibrosis pathways and preserve lung function. The study will enroll approximately 120 patients across placebo, low dose, and high dose groups at clinical sites in five countries. In addition to safety and tolerability, the trial will closely monitor changes in lung function, including forced vital capacity, a key tool in the measurement of respiratory health in patients with IPF. Rein expects to enroll patients through mid-2027, with interim data anticipated in the second half of 2026.